About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
RANOLAZINE demonstrates an exceptionally broad biochemical influence profile integrating multiaxis signalling interference, deep enzymatic cascade modulation, mitochondrialnetwork reprogramming, ionflux recalibration, structuralprotein remodelling, and transcriptionfactor pathway redistribution. Its conformational flexibility enables highaffinity docking to catalytic residues, regulatory allosteric sites, transmembrane helices, scaffolding complexes, and cytoskeletal polymers. This results in crosssystem modulation spanning metabolic, structural, genomic and stressadaptive biological layers.
Mechanistically, the compound can perturb phosphorylation landscapes, alter propagation velocity across MAPK, JNK, ERK, p38 and PI3KAKT pathways, shift Gprotein signalling bias, redistribute intracellular Ca²⁺ waveforms, modulate cAMPPKA activity, and influence mitochondrial ROS leakage thresholds. Secondary messenger amplification, membranepotential polarity adjustments and ATP/ADP cycle reshaping are frequently observed across experimental substrates.
Advanced
RANOLAZINE is applied in highprecision laboratory environments for:
- Deep kinomemapping and crosscascade interference modelling
- Receptorligand structural docking with metastability prediction
- Organellestress analysis including UPR, ER stress, mitochondrial oxidative load and mitophagy balance
- Multiomics transcriptome reconstruction with clustering of regulatory subnetworks
- Highresolution cytoskeletal dynamics mapping (actin tension, tubulin flux, scaffold integrity)
- Cellfate modelling across apoptosis, necroptosis, ferroptosis and autophagic flux states
- AIdriven SAR/QSAR modelling for compound performance optimisation
Toxicodynamics & Hazard Spectrum
At elevated or prolonged exposure, expected risks include:
- Acute ROS escalation with collapse of antioxidant buffering systems
- Mitochondrial fragmentation or electrontransport chain impairment
- Severe Ca²⁺/Na⁺/K⁺ ionchannel dysregulation
- Cytoskeletal depolymerisation causing mechanical instability
- Membrane rupture or lipidbilayer thinning
- Hyperactivation of inflammatory signalling (NF-κB, STAT families, IRF genes)
- Activation of programmed-cell-death pathways on multiple axes
- Epigenetic perturbation including methylation drift and histonemark imbalance
For expert not for any form of biological exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C24H33N3O4 |
|---|---|
| Molecular Weight | 427.5 g/mol |
| CAS Number | 95635-55-5 |
| Storage Condition | Store ranolazine tablets at 25 °C (77 °F) with excursion permitted to 15 to 30 °C (59 to 86 °F). |
| Solubility | <1 mg/ml |
| Purity | Purity information is available upon request (COA). |
| Synonym | RANOLAZINE; 95635-55-5; Ranexa; CVT-303; RAN D |
| IUPAC/Chemical Name | N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide |
| InChl Key | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
